

AD-A081 258

OKLAHOMA UNIV HEALTH SCIENCES CENTER OKLAHOMA CITY
CANINE AUTOANTICOAGULATION DURING EXTRACORPOREAL PERFUSION. (U)
DEC 79 L B HINSHAW, B BELLER-TODD, L T ARCHER N00014-79-C-0854
TR-140 NL

UNCLASSIFIED

1 1
257 6039 7545

END
DATE
FILMED
3 80
DOT

DISCLAIMER NOTICE

**THIS DOCUMENT IS BEST QUALITY
PRACTICABLE. THE COPY FURNISHED
TO DDC CONTAINED A SIGNIFICANT
NUMBER OF PAGES WHICH DO NOT
REPRODUCE LEGIBLY.**

OFFICE OF NAVAL RESEARCH

Contract ¹⁵NO 0014-79-C-0854

Task No. NR 207-207

⁹ TECHNICAL REPORT NO. 140

⁶ CANINE AUTOANTICOAGULATION DURING EXTRACORPOREAL PERFUSION

¹⁰ L. B. Hinshaw, B. Beller-Todd, L. T. Archer,
T. L. Murphy, F. B. Taylor, Jr., S. S. Sofer, and R. B. Passey

Prepared for Publication

in

American Journal of Physiology

Departments of Physiology & Biophysics, Internal Medicine, and Internal Medicine,
University of Oklahoma Health Sciences Center,
Oklahoma City, Oklahoma 73190

¹¹ 19 Dec 1979

Reproduction in whole or in part is permitted for
any purpose of the United States Government

Distribution of this report is unlimited

407464 x16

ABSTRACT

This laboratory has developed a procedure for extracorporeal perfusion without administration of anticoagulants. The present study was designed to determine extra- and intracorporeal requirements for the development of the incoagulable state, to investigate the biologic stability of the perfusion system, and to better define the nature of the hypocoagulable state. Anesthetized dogs were placed on extracorporeal perfusion without exogenous anticoagulation at flows exceeding 800 ml/min. Within 45 minutes of perfusion, blood drawn from the animal was incoagulable (clotting time >24 hr), and within 3 hours following discontinuation of perfusion, clotting time returned to normal. Requirements for the autoanticoagulated state were a perfused liver and a pump in the perfusion circuit. Injections of heparin, 100 U/kg, or use of either Tygon or latex tubing in the perfusion circuit, did not modify the time course of the development of the incoagulable state or its reversal following termination of perfusion. Arterial pressure, heart rate, glucose, platelet and fibrinogen concentrations were relatively constant ($p>0.05$); cortisol, white blood cell and neutrophil concentrations increased ($p<0.05$); while the activity of Factors V, VIII and X decreased ($p<0.05$).

INDEX TERMS: autoanticoagulation, perfusion without anticoagulation, new procedure for perfusion, extracorporeal perfusion, substitutes for exogenous anticoagulation, canine perfusion, improved perfusion, prolonged clotting time, endogenous anticoagulation, endogenous reversal of incoagulability

INTRODUCTION

Exogenously administered anticoagulants have long been considered essential for successful extracorporeal perfusion of man (3,15,16,33) and experimental animals (17,18). However, this anticoagulation, ordinarily obtained by heparin administration, has been associated with adverse side-effects including excessive loss of blood and leakage of fluid from surgical sites (21,33).

Examination of the problems associated with heparinization during extracorporeal perfusion has recently led to the development of perfusion systems that function without the use of exogenous anticoagulants (4,5,11-13). In recent studies employing both venovenous and arteriovenous perfusion systems without exogenous anticoagulation, it was demonstrated that a progressive prolongation of the Lee-White whole blood clotting times (WBCT) occurred until blood became incoagulable (WBCT >2 hr) after 45 minutes of perfusion (4,5). The animals suffered no adverse acute or chronic effects after 4 to 6 hours of perfusion; normal physiologic status was maintained, tissue pathology was negative; and animals were permanent healthy survivors (4,5). These studies (4,5,11-13) demonstrate that extracorporeal perfusion can be performed utilizing a controlled self-generating hypocoagulable state. A better understanding of this phenomenon may lead to improved management of anticoagulation during extracorporeal perfusion in man.

The purpose of the present study was to better define the intra- and extracorporeal requirements of this type of extracorporeal perfusion; to determine the stability of certain hemodynamic, metabolic, endocrinologic and hematologic parameters during and following perfusion, and to better characterize the autoanticoagulation phenomenon.

METHODS

Experimental Groups

Experiments were conducted on fifty adult dogs divided into four groups: Group 1 was composed of 17 perfused animals administered no exogenous anticoagulant; Group 2 was comprised of 12 dogs administered heparin, 100 U/kg, with six perfused and six not perfused serving as controls. Group 3 was composed of 12 eviscerated dogs perfused without exogenous anticoagulation, six with hepatic artery patent and six with hepatic artery ligated. Group 4 animals (N=9) were eviscerated, endotoxin was administered, and presence or absence of portal hypertension was used as an "in vivo" bioassay of possible collateral hepatic blood flow.

Selection of Animals

Animals selected for these experiments were adult mongrel dogs of random sex, screened for microfilaria, treated for intestinal parasites and allowed to stabilize 3 to 4 weeks. Only animals with white blood cell concentrations less than $21,000/\text{mm}^3$ and hematocrits exceeding 36% were utilized in the studies.

Surgical and Perfusion Procedures

Intact or eviscerated (see below) animals fasted overnight were prepared for extracorporeal perfusion after receiving intravenous sodium pentobarbital, 25 mg/kg body weight. The right brachial artery of each dog was cannulated to monitor mean systemic arterial pressure (MSAP) and heart rate and for sampling of blood. The basic extracorporeal system consisted of large-bore plastic tubing and plastic reservoir filled with saline (total volume of system about 500 ml). The proximal ends of the first set of saline-filled tubing (clamped with hemostats to prevent saline loss and blood reflux) were advanced into the distal aorta via the left and right femoral arteries.

The distal ends were secured below the surface of a 400-ml saline-filled reservoir placed within a water bath maintained at 40-42°C. Saline-filled tubing, attached to the bottom of the reservoir, was threaded through a roller-type pump and divided into a second set of cannulas which were then surgically inserted into the right and left femoral veins (these lines were also clamped with hemostats to prevent saline loss and blood reflux). Minimal pump occlusiveness was achieved by an adjustment of roller compression so that flow would not occur through the pump in the presence of a hydrostatic pressure gradient of 30 cm H₂O. To initiate the perfusion, all four clamps were simultaneously released with the pump set at a fixed flow rate (range, 800-1200 ml/min), and screw clamps on the arterial outflow lines were adjusted as necessary to maintain a constant level of blood in the reservoir. The pump flow rate was never varied, once established, during each experiment. In a separate series, rubber (latex) tubing was substituted for plastic (Tygon), and the reservoir was removed (see "Results" section).

Animals were eviscerated as follows: after midline laparotomy, the celiac, superior and inferior mesenteric arteries were ligated and divided between ligatures and the following procedure was carried out as previously described (1,17). The intestinal tract was doubly ligated and divided between ligatures at the distal esophagus subdiaphragmatically and at the distal rectum. Following ligation of the portal vein, all abdominal viscera except the liver were surgically removed from the animal, extreme care taken to prevent loss of blood. In half of the experiments, the hepatic artery was maintained patent by sectioning the celiac artery distal to the origin of the hepatic artery; in the other half, the celiac artery was divided near its origin at the aorta, thus preventing flow via the hepatic artery to the liver. Since the portal vein was ligated and sectioned, the liver was without blood flow

in the latter half of the experiments. Eviscerations were completed within 30 minutes, followed by a 30-minute equilibration period.

To confirm that hepatic blood flow was blocked by hepatic artery and portal vein ligation, we administered endotoxin to a series of animals. If portal pressure failed to increase, inflow of blood to hepatic tissue would be considered absent (17).

Prior to, and during, the perfusion period, no animals in Groups 1, 3 and 4 received an anticoagulant of any kind. All catheters and pressure transducers were filled and flushed with nonheparinized saline, and new tubing flushed thoroughly with saline was regularly employed in the perfusion circuit. Preperfusion parameters and blood samples were taken just prior to initiation of perfusion following an equilibration period.

Measurements: General Procedures

The following parameters were recorded in most experiments: mean systemic arterial pressure (MSAP), heart rate, rectal temperature, hematocrit, blood glucose concentration, extracorporeal blood flow rate, platelet and leukocyte concentrations. Coagulation tests included modified Lee-White whole blood clotting time (WBCT), prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen concentration, Factors V, VIII and X activities, fibrinogen degradation product (FDP) concentrations, and platelet aggregation to adenosine diphosphate (ADP) and thrombin.

MSAP and heart rate were monitored using a four-channel Hewlett-Packard recorder. Rectal temperature was obtained employing a Tele-Thermometer probe (Yellow Springs Instrument Co., Inc., Yellow Springs, Ohio). Hematocrit was measured with microhematocrit capillary tubes (Dade Diagnostics, Inc., Miami, Fla.) spun in an International micro-capillary centrifuge (International Equipment Co., Needham Heights, Mass). Blood glucose concentrations

were determined using a Beckman glucose analyzer (Beckman Instruments, Inc., Fullerton, CA). Blood flow was monitored via a calibrated roller-type pump (Medical Specialty Co., Fort Worth, TX) with periodic comparisons using a direct-timed volumetric procedure (see "Methods" section, *Perfusion Procedure*, for details). Platelets were counted using a method previously described (7). White blood cell (WBC) concentrations were obtained from a Coulter automatic particle counter (Coulter Electronics, Inc., Hialeah, FL) and WBC differential evaluations were conducted by staining blood smears with Wright's stain followed by examination with light microscopy. Serum cortisol was determined by radioimmunoassay according to a published procedure (8,22).

Measurements: Coagulation Parameters

Preparation of blood and plasma. Blood used to established normal coagulation control values was drawn from fasted beagle dogs from the external jugular vein using a two-syringe technique. Blood was drawn from the experimental animal's right brachial artery via polyethylene tubing. Both control and experimental blood samples were anticoagulated in Falcon plastic culture tubes using 3.8% sodium citrate (9 parts blood to 1 part anticoagulant).

Platelet-poor plasma was obtained by immediate centrifugation of citrated whole blood at 3000 g for 15 minutes and stored at -20°C in plastic culture tubes until coagulation tests were performed. Platelet-rich plasma used in platelet aggregation studies, performed on the day of each experiment, was prepared from citrated whole blood by centrifugation at 1000 g for 60 seconds in plastic culture tubes (Falcon). Platelet counts were performed using a Coulter automatic particle counter and platelet morphology checked by phase contrast microscopy.

Modified Lee-White whole blood clotting time. One cubic centimeter aliquots of whole blood drawn from the brachial artery were delivered

immediately into three 12x75 mm glass tubes. The tubes remained at room temperature and the first tube was tilted at intervals of 30 seconds until a solid clot formed. The second and third tubes were treated similarly in sequence. The recorded clotting time was the time required for a solid clot to form in the third tube (25).

Prothrombin time (PT). The one-stage prothrombin time was performed (37). First, 0.2 ml of a tissue thromboplastin (rabbit brain and lung) and CaCl_2 (0.0125 M) reagent (Simplastin; General Diagnostics, Morris Plains, N.J.) was heated to 37°C for 5 minutes in a plastic test vial. Then 0.1 ml of test plasma was added and a clotting time end point determined with a mechanical device (Clotek-Hyland Laboratories, Los Angeles, CA). The test was performed in triplicate and the mean of the three clotting times was recorded.

Activated partial thromboplastin time (APTT). The APTT was performed as described by Proctor and Rapaport (34). Test plasma (0.1 ml) plus 0.1 ml of a mixture of phospholipid emulsion from rabbit brain and micronized silica (General Diagnostics) was incubated at 37°C for 5 minutes. Then 0.1 ml of 0.025 M CaCl_2 was added and the clotting time end point determined with a mechanical device (Clotek-Hyland Laboratories). Test samples were run in triplicate and the mean result was recorded.

Fibrinogen concentration. The fibrinogen levels were determined by procedures described by Clauss (9). A clotting time was performed at 37°C by adding 0.1 ml of thrombin (bovine, 100 U/ml; Dade Diagnostics) to 0.2 ml test plasma (diluted 1:10 with barbitol-buffered saline). A standard curve was made using a commercially prepared fibrinogen solution (Data-Fi; Dade Diagnostics) diluted with barbitol-buffered saline. Clotting times were performed in duplicate and the mean value was used to determine the fibrinogen concentration from the standard curve.

Platelet aggregation. Citrated platelet-rich plasma (PRP) was stirred in a cuvette and transmittance of incident light, relative to a platelet-poor plasma (PPP) blank prepared from the same blood sample, was recorded using a Chronolog aggregometer (Chronolog, Havertown, PA). Aggregating agents, adenosine diphosphate (ADP) (Sigma Chemical Co., St. Louis, MO) and topical bovine thrombin (Parke-Davis & Co., Detroit, Mich.) were added to the PRP in final concentrations appropriate to produce reversible and irreversible aggregation. Increases in transmittance were used as an index of platelet aggregation (6,31).

Factor assays (V, VIII, X). A modified one-stage prothrombin time was used to measure Factor V (23) and Factor X (2) using human factor-deficient plasma (George King Bio-Medical, Overland Park, KS). A modified activated partial thromboplastin time was utilized to measure Factor VIII (24) levels using human factor VIII-deficient plasma (George King Bio-Medical). A standard curve was constructed using normal pooled citrated canine plasma and the factor-deficient plasma. Three dilutions of the test sample were assayed and a mean value was expressed as a percent of normal activity.

Fibrinogen degradation products (FDP). Fibrinogen degradation products were ascertained using the Thrombo-Wellcotest rapid latex test (Wellcome Research Laboratories, Beckenham, England). Antisera to purified human fibrinogen fragments D and E coat the latex particles, and FDPs in test serum cause the latex particles to clump. Serial dilutions of the test serum were then used to give semiquantitative results. The human antisera cross-react with canine FDPs allowing an estimate of levels to be made in comparison to normal (27,29).

Data Analysis

Data were analyzed using the students "t" test. Only values of less than 0.05 were considered statistically significant.

RESULTS

Table 1 describes various responses of a total of 11 animals to 3 hours of extracorporeal perfusion without exogenously administered anticoagulant, followed by 3 hours of recovery after cessation of perfusion. Lee-White whole blood clotting time increased from a control of 4 minutes to 21 minutes after 30 minutes of perfusion, and by 45 minutes blood removed for Lee-White clotting procedures failed to clot for a period greater than 24 hours (termed "infinite clotting time"). Following cessation of perfusion, clotting time returned to normal within 3 hours. Mean systemic arterial pressure (MSAP), heart rate, blood glucose, fibrinogen and platelet concentrations, prothrombin times, and rectal temperatures (T_{re}) were relatively constant during both 3 hours of perfusion and 3 hours of recovery, indicative of the stability of the preparation.

Striking changes indicated in Table 1 were seen in the following parameters. Cortisol concentrations increased during both perfusion and post-perfusion periods ($p < 0.05$), while white blood cell and neutrophil concentrations rose significantly during the post-perfusion period. Activities of Factors V, VIII and X fell markedly during perfusion ($p < 0.05$) but were insignificantly different from control values 3 hours after discontinuation of perfusion. The PT and PTT increased during perfusion in all animals; however, the changes failed to reach statistical significance due to the variability of the response.

Table 2 illustrates the effects of extracorporeal perfusion without exogenous anticoagulation on the ability of the platelets to aggregate and on the production of fibrinogen degradation products (FDP) in six of the dogs included in Table 1. On the average, decreased sensitivity to platelet aggregation induced by ADP or thrombin was seen during the 3-hour period of perfusion, while at termination of the recovery period (sixth hour), aggregation

was returning toward the normal (control). FDP levels during and following perfusion ranged from negative at five dilutions to a maximum of positive up to eighty dilutions.

The roles of both "extracorporeal" and "intracorporeal" components in the development of incoagulability are summarized in Table 3. Both Tygon (plastic) and latex (rubber) tubing or the presence of a reservoir had no effect on the development of "infinite clotting time", which was achieved in both instances by 45 minutes with or without a reservoir. Parallel experiments demonstrated that incoagulability of the blood in the absence of a reservoir could be obtained with as little as 33 inches total length of perfusion tubing with a volume of 45 ml; however, the presence of a pump was a requirement. Table 3 shows that recovery characteristics are essentially identical with latex or Tygon tubing, each requiring 3 hours following perfusion for return of clotting times to normal. All 11 animals recovered quickly and were euthanized 7 days after experimentation.

The evisceration studies with and without the hepatic artery ligated demonstrated that a functioning liver was required for the development of "infinite clotting time", but the remainder of the abdominal viscera was not necessary. Clotting time rose slightly, from 5 to 14 minutes in eviscerated dogs with hepatic artery ligation, but the subsequent pattern of autoanticoagulation after 30 minutes occurred only in those animals with the hepatic artery patent. In two of the studies in which the hepatic artery was ligated, clots were observed in the perfusion circuit. One of these animals died during the perfusion.

Data in Figure 1 suggest, however, that hepatic artery patency in eviscerated dogs does not influence MSAP and white blood cell and platelet

concentrations. MSAP fell gradually during perfusion; WBC concentrations fell early but returned to normal after 2 hours of perfusion, rising sharply above control during the 2-hour recovery period; and platelet concentrations showed a similar early trend, but otherwise remained relatively constant (range, 150-250,000/mm³).

To confirm that hepatic blood flow was completely blocked in the eviscerated dogs with both hepatic artery and portal vein ligations, a series was conducted using endotoxin as a test substance: Table 4 shows that a patent hepatic artery is essential for the development of portal hypertension after endotoxin. These experiments, therefore, provided reasonable assurance that hepatic artery and portal vein ligations in eviscerated dogs prevented blood from entering the liver, thus effectively removing it from the circulation.

Studies were conducted to determine if a low dose of heparin, administered prior to extracorporeal perfusion, would modify the autoanticoagulatory pattern illustrated in Table 1. Figure 2 provides data comparing three types of experimental maneuvers: non-perfused dogs given 100 U/kg heparin intravenously, perfused animals administered the same dosage, and perfused animals receiving no heparin.

Several significant observations emerged from these studies: (a) during the first 15 minutes of extracorporeal perfusion, both perfused groups demonstrated depressed clotting times compared to the non-perfused control ($p < 0.05$); (b) by 45 minutes, blood became incoagulable in both perfused groups, while clotting time was decaying in the non-perfused animals; and (c) prior heparinization at low dosages is without influence on the pattern and rate of development of the incoagulable state.

DISCUSSION

This laboratory has developed an extracorporeal perfusion system which functions successfully without the addition of an anticoagulant (4,5). During perfusion a hypocoagulable state is induced. No adverse effects on dogs subjected to 4 to 6 hours of perfusion have been noted, tissue pathology is negative, and animals are permanent healthy survivors.

The purpose of the present study was to advance our understanding of this unique perfusion procedure by identifying extra- and intracorporeal requirements; reaffirming the physiologic stability of the preparation; and further defining the nature of the hypocoagulable state.

Extra- and Intracorporeal Requirements

We have previously reported a procedural requirement that the tubing be saline-filled at the onset of perfusion and that blood flow rates in the extracorporeal system be maintained in excess of 400 ml/min (4,5). A major requirement of the perfusion apparatus was identified in this study. A pump was found to be necessary for the attainment of successful perfusion in the absence of an anticoagulant. Attempts to sustain a stable extracorporeal perfusion system without a pump in the perfusion circuit failed as evidenced by the precipitation of intravascular coagulation and death. The particular pump successfully employed in our studies is relatively atraumatic to the erythrocytes since there is no visible hemolysis after 6 hours of perfusion. Sublethal injuries precipitated by pump trauma to red and white blood cells and platelets undoubtedly occur, however, which might exert subtle effects on cellular function (39).

The type of tubing was not found to be a requirement for the development of extended clotting times in the present study since both latex (rubber) and Tygon (plastic) tubing used in the system produced similar patterns of incoagulability.

Since activation of the coagulation system might be another requirement for the promotion of the hypocoagulable state, heparin was given at the onset of perfusion. From these studies we observed that low doses of heparin (100 U/kg) given prior to perfusion (maximum clotting time <100 min) had no influence on the attainment of "infinite clotting times" (>24 hr) by 45 minutes of perfusion. However, it was noted that the clotting time rose less rapidly in perfused animals following this dose of heparin than in non-perfused controls given a similar dose of heparin ($p < 0.05$). This observation suggests that there is an early (15 min) hypercoagulable state, or heparin-resistant state, in the perfused animals. Another explanation, however, is that the concentration of heparin in the blood of perfused animals is decreased due to hemodilution by the saline in the extracorporeal system. The small changes in hematocrit after perfusion, however, indicate that the hemodilution is not great. In any event, this dosage of heparin did not interfere with, or accelerate, the development of the incoagulable state, although its employment might make it possible to use this procedure in humans by insuring that intravascular coagulation would not occur prior to the development of incoagulability.

Intracorporeal requirements were studied to determine essential organ systems influential in the development of autoanticoagulation. It was observed that a perfused liver was required for the development of the incoagulable state. Furthermore, if hepatic perfusion was present, all other abdominal visceral organs did not appear to be necessary in the development of, or recovery from, the hypocoagulable state. The role of the liver is not known; possibilities are that it is essential for the production of an intermediate factor which contributes to the development of incoagulability, or that it may be necessary for the removal of procoagulants.

Stability of Preparation

Consistent with data previously reported by our laboratory (4,5), animals in this study tolerated the extracorporeal perfusion without added heparin. The stability of the preparation is indicated by the relatively unchanging levels of mean arterial pressure, heart rate, blood glucose, fibrinogen and platelet concentrations. We believe the system exerts a mild stress on the animal since plasma cortisol concentrations increased during perfusion and subsequent elevations in white blood cell and neutrophil concentrations occurred during the recovery period. As previously reported (4), all non-eviscerated animals perfused on our system were permanent healthy survivors.

Characterization of the Autoanticoagulated State

Previous investigators have perfused dogs on extracorporeal systems containing blood oxygenators without administering heparin (11-13,32). In these earlier studies, the fibrinogen level (11-13,32) and platelet count (11,13) decreased and the PT, PTT, FDP (11-13) and WBCT (11,12) increased. These changes in the coagulation tests are also reported during disseminated intravascular coagulation (28) with an associated activation of the fibrinolytic system (10).

Our group has reported that dogs perfused using an arteriovenous extracorporeal system with no oxygenator present in the circuit developed WBCT values greater than 24 hours (4,5). This autoanticoagulated state has been further characterized in the current study. Dogs perfused on our extracorporeal system without heparin administration developed a progressive increase in the whole blood clotting time associated with decreases in Factors V, VIII and X activities. The platelet and fibrinogen levels remained relatively stable.

Why is the blood in this system incoagulable? One theory is that the animal is experiencing disseminated intravascular coagulation (DIC). Decreases in Factors V, VIII and X activities similar to those observed in this study have been reported by some investigators after cardiopulmonary bypass performed with heparin administration in man (21) and associated with DIC in man (28) and the dog (14). However, the platelet and fibrinogen concentrations which usually decrease during intravascular coagulation (14,28) did not significantly change in the present study, suggesting that another process (besides DIC) may be responsible for the state of autoanticoagulation.

The elevations of FDP values observed during our perfusion indicate that the fibrinolytic system is activated (10). It is unlikely, however, that this is the primary cause of the incoagulability. Good hemostasis was maintained at surgical sites throughout the study. In addition, the expected decrease in fibrinogen levels reported when fibrinolysis produces a hypo-coagulable state (10,23) was not observed in our study. The levels of fibrinogen in our system, however, might not reflect the degree of fibrinolysis if fibrinogen production were accelerated.

A phenomenon which may have contributed to the prolongation of the whole blood clotting time was a change in the reactivity of the platelets. Platelet sensitivity to ADP and thrombin-induced aggregation decreased during perfusion in our experiments. Previous workers have also noted a decrease in ADP-induced aggregation after cardiopulmonary bypass, but the reason is not understood (21).

We have discovered that a plasma inhibitor is generated during the perfusion (see companion paper by Murphy et al., ref. 30). Fibrinogen degradation product concentrations (23) and endogenous heparin (19,20) are inhibitors which have been found in dog plasma in certain experimental situations and either could

theoretically be the major cause of the state of autoanticoagulation produced with our perfusion system. However, the inhibitor we have discovered has heparin-like characteristics in that it accelerates the inhibition of thrombin and Factor Xa by antithrombin III, is heat-stable, and is adsorbed from plasma with BaSO_4 (see companion paper, 30).

The inhibitor with heparin-like activity produced in this extracorporeal perfusion system without exogenous anticoagulation is described further in a companion paper (30). Heparin is known to prolong whole blood clotting time and PT and PTT values, inhibit thrombin- and possibly ADP-induced platelet aggregation (38), and at high levels heparin may interfere with the clotting assays used to measure Factors V, VIII and X. Consequently, the elaboration of a heparin-like substance would seem to explain many of the findings in the present study.

REFERENCES

1. Archer, L. T., B. Benjamin, M. M. Lane, and L. B. Hinshaw. Renal gluconeogenesis and increased glucose utilization in shock. Am. J. Physiol. 231: 872-879, 1976.
2. Bachmann, F., F. Duckert, and F. Koller. The Stuart-Prower factor assay and its clinical significance. Thromb. Diath. Haemorrh. 2: 24-38, 1958.
3. Bachmann, F., R. McKenna, E. R. Cole, and H. Najafi. The hemostasis mechanism after open-heart surgery. I. Studies on plasma coagulation factors and fibrinolysis in 512 patients after extracorporeal circulation. J. Thorac. Cardiovasc. Surg. 70: 76-85, 1975.
4. Beller, B. K., L. T. Archer, S. D. Kosanke, and L. B. Hinshaw. Extracorporeal perfusion without anticoagulation and the response to endotoxin. Surg. Gynecol. Obstet. 148: 679-684, 1979.
5. Beller-Todd, B., L. T. Archer, and L. B. Hinshaw. Recovery from endotoxin shock after extracorporeal perfusion without anticoagulation. Circ. Shock, in press.
6. Born, G. V. R. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 194: 927-929, 1962.
7. Brecher, G., and E. P. Cronkite. Morphology and enumeration of human blood platelets. J. Appl. Physiol. 3: 365-377, 1950.
8. Brenner, P. F., R. Guerro, Z. Cekan, and E. Diczfalusy. Radioimmunoassay method for six steroids in human plasma. Steroids 22: 775-794, 1973.
9. Clauss, V. A. Gerinnungsphysiologische schnellmethode zur bestimmung des fibrinogens. Acta Haematol. 17: 237-246, 1957.
10. Fletcher, A. P., N. Alkjaersig, and S. Sherry. Pathogenesis of the coagulation defect developing during pathological plasma proteolytic

("fibrinolytic") states. I. The significance of fibrinogen proteolysis and circulating fibrinogen breakdown products. J. Clin. Invest. 41: 896-916, 1962.

11. Fletcher, J. R., A. E. McKee, M. Mills, K. C. Snyder, and C. M. Herman. Twenty-four hour membrane oxygenation in dogs without anticoagulation. Surgery 80: 214-223, 1976.
12. Fletcher, J. R., A. E. McKee, and C. M. Herman. Membrane oxygenation in baboons without anticoagulants. J. Surg. Res. 22: 273-280, 1977.
13. Fletcher, J. R., A. McKee, R. Anderson, and L. Watson. Baboon veno-arterial cardiopulmonary bypass without anticoagulants. Amer. Soc. Artif. Intern. Organs 24: 315-319, 1978.
14. Garner, R., B. V. Chater, and D. L. Brown. The role of complement in endotoxin shock and disseminated intravascular coagulation: experimental observations in the dog. Brit. J. Haematol. 28: 393-401, 1974.
15. Gralnick, H. R., and R. D. Fischer. The hemostatic response to open-heart operations. J. Thorac. Cardiovasc. Surg. 61: 909-915, 1971.
16. Heiden, D., C. H. Mielke, Jr., R. Rodvien, and J. D. Hill. Platelets, hemostasis, and thromboembolism during treatment of acute respiratory insufficiency with extracorporeal membrane oxygenation. Experience with 28 clinical perfusions. J. Thorac. Cardiovasc. Surg. 70: 644-655, 1975.
17. Hinshaw, L. B., R. P. Gilbert, H. Kuida, and M. B. Visscher. Peripheral resistance changes and blood pooling after endotoxin in eviscerated dogs. Amer. J. Physiol. 195: 631-634, 1958.
18. Hinshaw, L. B., and S. E. Owen. Correlation of pooling and resistance changes in the canine forelimb in septic shock. J. Appl. Physiol. 30: 331-337, 1971.

19. Howell, W. H. The purification of heparin and its presence in blood. Amer. J. Physiol. 71: 553-562, 1925.
20. Jaques, L. B., and E. T. Waters. The identity and origin of the anti-coagulant of anaphylactic shock in the dog. J. Physiol. 99: 454-466, 1941.
21. Kalter, R. D., C. M. Saul, L. Wetstein, C. Soriano, and R. F. Reiss. Cardiopulmonary bypass. Associated hemostatic abnormalities. J. Thorac. Cardiovasc. Surg. 77: 427-435, 1979.
22. Kling, O. R., and P. K. Westphal. Steroid changes during the menstrual cycle of the baboon (*Papio cynocephalus*) and human. Biol. Reprod. 18: 392-400, 1978.
23. Kowalski, E., A. Z. Budzynski, M. Kopec, Z. S. Latallo, B. Lipinski, and Z. Wegrzynowicz. Studies on the molecular pathology and pathogenesis of bleeding in severe fibrinolytic states in dogs. Thromb. Diath. Haemorrh. 11: 69-86, 1964.
24. Langdell, R. D., R. H. Wagner, and K. M. Brinkhous. Effect of anti-hemophilic factor on one-stage clotting tests. A presumptive test for hemophilia and a simple one-stage antihemophilic factor assay procedure. J. Lab. Clin. Med. 41: 637-647, 1955.
25. Lee, R. I., and P. D. White. A clinical study of the coagulation time of blood. Amer. J. Med. Sci. 145: 495-503, 1913.
26. Lewis, M. L., and A. G. Ware. A one-stage method for the determination of accelerator globulin. Proc. Soc. Exptl. Biol. Med. 84: 640-643, 1950.
27. Merskey, C., G. J. Kleiner, and A. J. Johnson. Quantitative estimation of split products of fibrinogen in human serum, relation to diagnosis and treatment. Blood 28: 1-18, 1966.
28. Merskey, C., A. J. Johnson, G. J. Kleiner, and H. Wohl. The defibrination syndrome: clinical features and laboratory diagnosis. Brit. J. Haemat. 13: 528-549, 1967.

29. Murakami, M. An immunological method for demonstrating fibrin or fibrinogen degradation products in the circulating blood. Acta Haemat. Jap. 28: 341-344, 1965.
30. Murphy, T. L., F. J. Walker, F. B. Taylor III, B. K. Beller-Todd, L. T. Archer, S. S. Sofer, and L. B. Hinshaw. Endogenous anticoagulation during extracorporeal perfusion in the dog: generation of a heparin-like inhibitor. (Companion paper submitted for publication.)
31. O'Brien, J. R. Platelet aggregation. II. Some results from a new method of study. J. Clin. Pathol. 14: 452-455, 1962.
32. Osborn, J. J., R. MacKenzie, A. Shaw, H. Perkins, R. Hurt, and F. Gerbode. Cause and prevention of hemorrhage following extracorporeal circulation. Surg. Forum 6: 96-100, 1956.
33. Phillips, L. L., J. R. Malm, and R. A. Deterling, Jr. Coagulation defects following extracorporeal circulation. Ann. Surg. 157: 317-326, 1963.
34. Proctor, R. R., and S. I. Rapaport. The partial thromboplastin time with kaolin; a simple screening test for first stage plasma clotting factor deficiencies. Amer. J. Clin. Pathol. 36: 212-219, 1961.
35. Quick, A. J. Hemorrhagic Diseases and Thrombosis. (Second Edition.) Philadelphia: Lea & Febiger, 1966.
36. Sutura, S. P. Flow-induced trauma to blood cells. American Heart Association Monograph No. 62, 1978, pp. 33-39.
37. Wintrobe, M. M., G. R. Lee, D. R. Boggs, T. C. Bithell, J. W. Athens, and J. Foerster. Clinical Hematology. (Seventh Edition.) Philadelphia: Lea & Febiger, 1974, p. 1207.
38. Zucker, M. B. Biological aspects of heparin action. Fed. Proc. 36: 47-49, 1977.

TABLE 1. Response of intact dogs to extracorporeal perfusion without exogenous anticoagulation (Group 1)

Parameter	N	Time (min)											
		Perfusion								Perfusion discontinued			
		0 ²	15	30	45	60	90	120	180	240	300	360	
Lee-White whole blood clotting time (min)	11	4.3 (0.3)	9.9 (0.9)*	21.2 (1.6)*	∞ *	∞ *	∞ *	∞ *	∞ *	68.5 (9.1)*	19.7 (1.4)*	5.4 (0.7)	
MSAP (mmHg)	11	139 (4)	133 (6)*	127 (6)*	126 (5)*	124 (6)*	124 (7)*	126 (6)*	131 (5)	137 (3)	131 (5)*	126 (4)	
Heart rate (/min)	11	158 (11)	186 (7)*	177 (7)*	178 (6)*	172 (6)	172 (8)	177 (6)	167 (6)	146 (9)	170 (5)	175 (10)	
Hematocrit (vol %)	11	40.4 (1.2)	37.7 (1.3)*	37.6 (1.6)*	37.5 (1.5)*	38.4 (1.6)*	38.7 (1.7)	39.3 (1.5)	37.7 (1.3)*	37.5 (1.0)*	38.5 (1.0)*	39.0 (0.9)*	
Rectal temperature (°C)	11	38.6 (0.2)	38.5 (0.2)	38.4 (0.2)	38.5 (0.1)	38.5 (0.1)	38.5 (0.1)	38.6 (0.1)	38.7 (0.1)	39.3 (0.2)*	39.6 (0.2)*	39.7 (0.2)*	
Extracorporeal blood flow (ml/min)	11	864 (78)	873 (77)	867 (78)	863 (79)	864 (78)	869 (80)	875 (80)					
Blood glucose (mg/dl)	11	121 (2)	121 (2)	121 (3)	120 (3)	126 (3)	122 (4)	120 (3)	117 (3)	118 (2)	113 (3)	115 (4)	
Serum cortisol (mg/ml)	8	154 (42)	209 (40)*				206 (24)	235 (26)*	249 (34)*	254 (47)*	198 (33)		
Total WBC (/mm ³)	11	10363 (1190)					6127 (750)*	8936 (1332)	13909 (2093)*	17800 (2610)*	21175 (2919)*		
Mature neutrophils (/mm ³)	10	6817 (1041)					4406 (696)*	7114 (1409)	11359 (2315)*	14880 (2830)*	18024 (3207)*		
Immature neutrophils (/mm ³)	10	58 (29)					308 (159)	615 (235)*	1179 (400)*	1676 (477)*	2051 (468)*		

Table 1 (continued)

	0	15	30	60	90	120	180	240	300	360
Fibrinogen (mg/dl)	6	340 (64)	358 (76)	358 (58)			330 (49)			375 (58)
Platelets ($\times 10^3/\text{mm}^3$)	10	211.2 (29.8)	184.4 (20.8)		197.8 (20.9)		183.1 (21.1)	169.0 (15.4)*		182.2 (20.7)
Factor VIII (% activity)	6	101.7 (1.1)	32.7 (20.3)*	24.2 (8.9)*			14.2 (8.3)*			75.5 (20.2)
Factor V (% activity)	6	99.8 (1.1)	55.4 (12.7)*	66.5 (18.2)			64.8 (17.0)			108.8 (28.0)
Factor X (% activity)	6	99.7 (1.0)	48.4 (13.8)*	43.2 (7.1)*			40.2 (11.3)*			82.8 (16.5)
Prothrombin time (sec)	6	7.4 (0.4)	9.6 (1.5)	11.1 (2.1)			8.6 (0.7)			7.5 (0.3)
Activated partial thromboplastin time (sec)	6	20.3 (1.0)	73.0 (18.6)*	107.0 (35.9)			72.9 (35.8)			24.2 (2.0)

Values are mean($\pm$ SE).

∞ = no visible clotting during 24 hours.

*p<0.05, paired comparison to 0 time value.

Measurements taken prior to beginning perfusion.

TABLE 2. Effects of extracorporeal perfusion without exogenous anticoagulation on platelet aggregation and fibrinogen degradation products (FDP) in intact dogs (Group 1)

		Time (minutes)											
		Perfusion				Perfusion discontinued							
		0 ^a				180				360			
		NA ^b	RA ^b	IRA ^b	NA	RA	IRA	NA	RA	IRA	NA	RA	IRA
Platelet aggregation ^c													
Adenosine diphosphate (ADP); (μmoles)	N	2.6 (0.6)	6.0 (1.0)	3.2 (0.7)	7.0 (1.2)	4.4 (0.6)	9.0 (1.0)	5.8 (1.8)	12.0 (3.4)	4.7 (1.9)	10.0 (2.7)		
		5 ^d	5	5	5	5	5	5	5	4	5		
Platelet aggregation ^e													
Thrombin (units/ml)	1	0.4		2.0	4.0	4.0	8.0	4.0	8.0	2.0	4.0		
	2	f	f	2.0	8.0	4.0	8.0	4.0	8.0		0.4		
	3		0.4	4.0	8.0	4.0	8.0	2.0	4.0		0.4		
	4		0.4	8.0		8.0	8.0	8.0		0.4	2.0		
	5		0.4	8.0		8.0	8.0	8.0		0.4	4.0		
	6	0.4	2.0	4.0	8.0	8.0	8.0	8.0		0.4	2.0		
FDP ^f (dilutions) ^h													
		0				60				360			
		<5				>5<40				>5<40			

^aMeasurements taken prior to beginning perfusion.

^bNA = no aggregation; RA = reversible aggregation; IRA = irreversible aggregation

^cValues are mean(SD); final concentration in μmoles.

^dOne animal excluded based on the fact that at 0 time (before perfusion), 20 μmoles of ADP was necessary to aggregate platelets irreversibly.

^eValues given are individual experiments (1-6).

^fAmount not taken. ^gFibrinogen degradation products.

^hRange of values.

TABLE 2. Effects of extracorporeal perfusion without exogenous anticoagulation on platelet aggregation and fibrinogen degradation products (FDP) in intact dogs (Group 1)

		Time (minutes)											
		Perfusion				Perfusion discontinued							
		0 ^a				180				360			
		NA ^b	RA ^b	IRA ^b	NA	RA	IRA	NA	RA	IRA	NA	RA	IRA
Platelet aggregation ^c													
Adenosine diphosphate (ADP); (μmoles)		2.6 (0.6)	6.0 (1.0)	3.2 (0.7)	7.0 (1.2)	4.4 (0.6)	9.0 (1.0)	5.8 (1.8)	12.0 (3.4)	4.7 (1.9)	10.0 (2.7)		
N		5 ^d	5	5	5	5	5	5	5	4	5		
Platelet aggregation ^e													
Thrombin (units/ml)		1	0.4	2.0	4.0	4.0	8.0	4.0	8.0	2.0	4.0		
2		f	f	2.0	8.0	4.0	8.0	4.0	8.0	0.4	0.4		
3			0.4	4.0	8.0	4.0	8.0	2.0	4.0	0.4	0.4		
4			0.4	8.0	8.0	8.0	8.0	8.0	0.4	2.0	2.0		
5			0.4	8.0	8.0	8.0	8.0	8.0	0.4	4.0	4.0		
6		0.4	2.0	4.0	8.0	8.0	8.0	8.0	0.4	2.0	2.0		
FDP ^g (dilutions) ^h		0	15	60	180	360							
		<5	>5<80	>5<40	>5<40	>5<20							

^aMeasurements taken prior to beginning perfusion.

^bNA = no aggregation; RA = reversible aggregation; IRA = irreversible aggregation

^cValues are mean(±SE); final concentration in μmoles.

^dOne animal excluded based on the fact that at 0 time (before perfusion), 20 μmoles of ADP was necessary to aggregate platelets irreversibly.

^eValues given are individual experiments (1-6).

^fMeasurement not taken. ^gFibrinogen degradation products.

^hRange of values.

TABLE 3. Effect of extracorporeal perfusion without exogenous anticoagulation on clotting time (in minutes)^a in intact and eviscerated dogs (Groups 1 and 3)

	N	Time (minutes)									
		0 ^b	15	30	45	60	90	120	180	210	Perfusion discontinued
intact perfused dogs (Tygon tubing and reservoir)	11	4.3 (0.3)	9.9 (0.9)*	21.2 (1.6)*	∞*	∞*	∞*	∞*	∞*	∞*	68.5 (9.1)*
intact perfused dogs (latex tubing; no reservoir)	6	4.3 (0.7)	12.8 (1.4)*	22.0 (0.9)*	∞*	∞*	∞*	∞*	∞*	43.3 (1.0)*	19.7 (1.4)*
eviscerated perfused dogs (hepatic artery patent)	6	5.3 ^e (0.2)	16.0 (0.5)*	28.0 (1.9)*	∞*	∞*	∞*	∞*	47.4 (4.7)*	26.4 (3.1)*	12.3 (2.4)*
eviscerated perfused dogs (hepatic artery ligated)	6	5.0 ^e (0.4)	13.5 (1.6)*	10.3 (0.8)*	8.8 (0.3)*	8.0 (0)*	7.5 (0.6)*	7.5 (0.7)	5.8 (0.3)	5.3 (0.5)	5.0 (0)

Values are mean (SD). *Indicates paired comparison to control (0 time) values in intact dogs and to post-evisceration control values in eviscerated dogs, $p < 0.05$.

∞ = no visible clotting time during 24 hours.

the arterial whole blood clotting time, using a modified Lee and White (25) procedure.

Measurements taken prior to beginning perfusion.

Re-evisceration control values.

Measurements taken prior to beginning perfusion and after evisceration procedure (post-evisceration control).

TABLE 4. Effect of LD₁₀₀ endotoxin on portal vein pressure in eviscerated dogs with and without patent hepatic artery* (Group 4)

Animal No.	Pre-endotoxin		Post-endotoxin ^a	
	MSAP ^b	PVP ^c	MSAP	PVP
<i>Series 1: Hepatic Artery Patent</i>				
1	135	8	90	18
2	125	3	135	15
3	135	6	125	21
4	150	7	140	16
<i>Series 2: Hepatic Artery Ligated</i>				
1	160	6	165	2
2	155	6	105	3
3	155	3	155	2
4	160	3	160	3
5	155	4	155	5

*Portal vein ligated in both instances, with all abdominal viscera excluding liver surgically removed.

^a maximum change in portal vein pressure, 15-30 min post-endotoxin

^b MSAP = mean systemic arterial pressure (mmHg)

^c PVP = portal vein pressure (mmHg)




FIGURE 1. Responses of eviscerated dogs during and following extracorporeal perfusion without exogenous anticoagulation (mean $\pm$ SE); Groups 1 & 3




FIGURE 2. Comparison of effects of exogenously administered heparin with endogenously-induced anticoagulation in dogs during extracorporeal perfusion (mean $\pm$ SE) ; Group 2

UNCLASSIFIED

SECURITY CLASSIFICATION OF THIS PAGE (When Data Entered)

REPORT DOCUMENTATION PAGE		READ INSTRUCTIONS BEFORE COMPLETING FORM
1. REPORT NUMBER Technical Report No. 140	2. GOVT ACCESSION NO.	3. RECIPIENT'S CATALOG NUMBER
4. TITLE (and Subtitle) Canine Autoanticoagulation During Extracorporeal Perfusion		5. TYPE OF REPORT & PERIOD COVERED Technical Report
7. AUTHOR(s) L. B. Hinshaw, B. Beller-Todd, L. T. Archer, T. L. Murphy, F. B. Taylor, Jr., S. S. Sofer		6. PERFORMING ORG. REPORT NUMBER No. 140
9. PERFORMING ORGANIZATION NAME AND ADDRESS & R. B. Passey Univ. of Oklahoma Health Sci. Ctr/ Oklahoma City, OK 73190		8. CONTRACT OR GRANT NUMBER(s)
11. CONTROLLING OFFICE NAME AND ADDRESS Office of Naval Research Arlington, VA		10. PROGRAM ELEMENT, PROJECT, TASK AREA & WORK UNIT NUMBERS
14. MONITORING AGENCY NAME & ADDRESS (if different from Controlling Office)		12. REPORT DATE 19 December 1979
		13. NUMBER OF PAGES 26
		15. SECURITY CLASS. (of this report)
		15a. DECLASSIFICATION/DOWNGRADING SCHEDULE
16. DISTRIBUTION STATEMENT (of this Report) Distribution of this report is unlimited		
17. DISTRIBUTION STATEMENT (of the abstract entered in Block 20, if different from Report)		
18. SUPPLEMENTARY NOTES		
19. KEY WORDS (Continue on reverse side if necessary and identify by block number) autoanticoagulation, perfusion without anticoagulation, new procedure for perfusion, extracorporeal perfusion, substitutes for exogenous anticoagulation, canine perfusion, improved perfusion, prolonged clotting time, endogenous anticoagulation		
20. ABSTRACT (Continue on reverse side if necessary and identify by block number) This laboratory has developed a procedure for extracorporeal perfu- sion without administration of anticoagulants. The present study was designed to determine extra- and intracorporeal requirements for the development of the incoagulable state, to investigate the biologic stability of the perfusion system, and to better define the nature of the hypocoagulable state. Anesthetized dogs were placed on extra- corporeal perfusion without exogenous anticoagulation at flows		

DD FORM 1473

EDITION OF 1 NOV 65 IS OBSOLETE
S/N 0102-LF-014-6601

UNCLASSIFIED

SECURITY CLASSIFICATION OF THIS PAGE (When Data Entered)

UNCLASSIFIED

SECURITY CLASSIFICATION OF THIS PAGE (When Data Entered)

exceeding 800 ml/min. Within 45 minutes of perfusion, blood drawn from the animal was incoagulable (clotting time >24 hr), and within 3 hr following discontinuation of perfusion, clotting time returned to normal. Requirements for the autoanticoagulated state were a perfused liver and a pump in the perfusion circuit. Injections of heparin, 100 U/kg, or use of either Tygon or latex tubing in the perfusion circuit, did not modify the time course of the development of the incoagulable state or its reversal following termination of perfusion. Arterial pressure, heart rate, glucose, platelet and fibrinogen concentrations were relatively constant ($p > 0.05$); cortisol, white blood cell and neutrophil concentrations increased ($p < 0.05$); while the activity of Factors V, VIII and X decreased ($p < 0.05$).

UNCLASSIFIED

SECURITY CLASSIFICATION OF THIS PAGE (When Data Entered)

OFFICE OF NAVAL RESEARCH
BIOLOGICAL SCIENCES DIVISION
BIOPHYSICS PROGRAM, Code 444
DISTRIBUTION LIST FOR TECHNICAL, ANNUAL AND FINAL REPORTS

Number of Copies

(13)	Administrator, Defense Documentation Center Cameron Station Alexandria, Virginia 22314
(6)	Director, Naval Research Laboratory Attention: Technical Information Division Code 2627 Washington, D. C. 20375
(6)	Office of Naval Research Attention: Code 102IP (ONRL DOC) 800 N. Quincy Street Arlington, Virginia 22217
(3)	Office of Naval Research Biophysics Program Code 444 Arlington, Virginia 22217
(2)	Commanding Officer Naval Medical Research and Development Command National Naval Medical Center Bethesda, Maryland 20014
(2)	Chief, Bureau of Medicine and Surgery Department of the Navy Washington, D. C. 20375
(2)	Technical Reference Library Naval Medical Research Institute National Naval Medical Center Bethesda, Maryland 20014
(2)	Office of Naval Research Branch Office Building 114, Section D 666 Summer Street Boston, Massachusetts 02210
(2)	Office of Naval Research Branch Office 536 South Clark Street Chicago, Illinois 60605

- (1) Office of Naval Research Branch Office
1030 East Green Street
Pasadena, California 91106
- (1) Commanding Officer
Naval Medical Research Unit No. 2
Box 14
APO San Francisco 96263
- (1) Commanding Officer
Naval Medical Research Unit No. 3
FPO New York 09527
- (1) Officer in Charge
Submarine Medical Research Laboratory
Naval Submarine Base, New London
Groton, Connecticut 06342
- (1) Scientific Library
Naval Aerospace Medical Research Institute
Naval Aerospace Medical Center
Pensacola, Florida 32512
- (1) Commanding Officer
Naval Air Development Center
Attn: Aerospace Medical Research Department
Warminster, Pennsylvania 18974
- (1) DIRECTOR
Naval Biosciences Laboratory
Building 801
Naval Supply Center
Oakland, California 94625
- (1) Commander, Army Research Office
P. O. Box 12211
Research Triangle Park
North Carolina 27709
- (1) DIRECTORATE OF LIFE SCIENCES
Air Force Office of Scientific Research
 Bolling Air Force Base
Washington, D. C. 20332
- (1) Commanding General
Army Medical Research and Development Command
Forrestal Building
Washington, D. C. 20315

(1)

Department of the Army
U. S. Army Science and
Technology Center - Far East
APO San Francisco 96328

(1)

Assistant Chief for Technology
Office of Naval Research, Code 200
800 N. Quincy Street
Arlington, Virginia 22217